Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
MonumentTAL-3: 64407564MMY3002: A Phase III Randomized Study Comparing Talquetamab SC in Combination with Daratumumab SC and Pomalidomide Tal-DP or Talquetamab SC in Combination with Daratumumab SC Tal-D versus Daratumumab SC, Pomalidomide and Dexamethasone DPd, in Participants with Relapsed or Refractory Multiple Myeloma who Have Received at Least 1 Prior Line of Therapy
Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma
A Phase III, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Mezigdomide CC-92480, Bortezomib And Dexamethasone MEZIVd Versus Pomalidomide, Bortezomib And Dexamethasone PVd In Subjects With Relapsed Or Refractory Multiple Myeloma RRMM: SUCCESSOR-1
A Randomized Phase II Study Comparing Cytarabine + Daunorubicin 7+3 vs Daunorubicin and Cytarabine Liposome, Cytarabine + Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and Daunorubicin and Cytarabine Liposome + Venetoclax in Patients Aged 59 or Younger Who are Considered High-Risk Adverse Acute Myeloid Leukemia as Determined by MYELOMATCH; A MYELOMATCH CLINICAL TRIAL
Open Label, Multicenter, Long-Term Follow-Up Study for Subjects Treated with P-BCMA-101
A Phase III, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Treatment after Autologous Stem Cell Transplantation ASCT in Participants with Newly Diagnosed Multiple Myeloma NDMM
Expanded Access Protocol EaP For Subjects Receiving Idecabtagene vicleucel That Is Nonconforming For commercial Release
Study Type: Treatment
Phase: N/A
NCTID: NCT04771078
Principal Investigator:
Nausheen Ahmed